Abstract
Background The Nine-Hole Peg Test (9HPT) is the golden standard in clinical practice to measure manual dexterity in people with multiple sclerosis (MS). However, administration requires trained personnel and dedicated time during a clinical visit.
Objective To validate a smartphone-based test for remote manual dexterity assessment, the icompanion Finger Dexterity Test (FDT), to be included into the icompanion application.
Methods 65 MS and 81 healthy subjects performed a first testing session, and 21 healthy subjects performed a second session approximately two weeks later.
Results The FDT significantly correlated with the 9HPT (dominant: Spearman’s ρ=0.62, p<0.001; non-dominant: ρ=0.52, p<0.001). FDT scores showed a significant difference between the MS and healthy subjects (dominant: Cohen’s d=0.24, p=0.015; non-dominant: Cohen’s d=0.18, p=0.013), which was not the case for the 9HPT. A significant correlation with age (dominant: ρ=0.46, p<.001; non-dominant: ρ=0.40, p=0.002), Expanded Disability Status Scale (EDSS, dominant: ρ=0.37, p=0.004; non-dominant: ρ=0.33, p=0.017), and disease duration for the non-dominant hand (ρ=0.31, p=0.016) was observed.
Conclusion The icompanion Finger Dexterity Test shows a moderate-to-good concurrent validity, ecological validity and test-retest reliability, and differentiates between the MS subjects and healthy controls. This test can be implemented into routine MS care for remote follow-up of manual dexterity.
Competing Interest Statement
Delphine Van Laethem is funded by an FWO PhD fellowship (1SD5322N, www.fwo.be). Stijn Denissen prepares a PhD with icometrix as industrial partner, funded by a personal industrial PhD grant (Baekeland, HBC.2019.2579) appointed by Flanders Innovation and Entrepreneurship, and received a personal travel grant (V412023N) from the Fonds Wetenschappelijk Onderzoek (FWO) for his stay in Prague in the context of his PhD. Johan Baijot: nothing to disclose. Lars Costers is an employee of icometrix. Annabel Descamps is an employee of icometrix. Ann Van Remoortel: nothing to disclose. Annick Van Merhaegen–Wieleman: nothing to disclose. Marie Beatrice D’hooghe : nothing to disclose. Miguel D’Haeseleer: nothing to disclose. Dirk Smeets is an employee and shareholder of icometrix. Diana Sima is an employee of icometrix. Jeroen Van Schependom: nothing to disclose. Guy Nagels is minority shareholder of icometrix, on a 10% secondment from the UZ Brussel to icometrix as medical director and a senior clinical research fellow of the FWO Flanders (1805620N, www.fwo.be).
Funding Statement
Delphine Van Laethem is funded by an Fonds Wetenschappelijk Onderzoek (FWO) Flanders PhD fellowship (1SD5322N, www.fwo.be). Stijn Denissen is funded by a personal industrial PhD grant (Baekeland, HBC.2019.2579) appointed by Flanders Innovation and Entrepreneurship. Guy Nagels is a senior clinical research fellow of the FWO Flanders (1805620N). This study is in part funded through the CLAIMS project, which is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112153. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, AB Science SA and icometrix NV.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical committees of the Universitair Ziekenhuis Brussel and the National Multiple Sclerosis Center Melsbroek gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared first authors
Funding statement was adapted.
Data Availability
The source data and the code used for the statistical analysis and the creation of the figures will be made available in the GitHub repository of our lab, in a sub-repository named smartphone_tests.
